Skip to main content

Table 2 Baseline characteristics of the included studies

From: Serum anti-phospholipase A2 receptor (PLA2R) antibody detected at diagnosis as a predictor for clinical remission in patients with primary membranous nephropathy: a meta-analysis

First author

Year

Race

Age

Sex (M/F)

Diagnosis

PRO (g/d)

CREA (mg/dl)

Fo (mo)

DD (mo)

IST n(n%)

TTR (mo)

Sample (n)

sPLA2R-ab(+) n (n%)

sPLA2R-ab (−) n (n%)

AM

Hofstra JM [13]

2012

No-As

51.6 ± 16.0

96/26

RB

10.2 (3.6–37.9)

95 (51–302)

54

NA

NA

NA

109

79 (72.5%)

28 (25.7%)

ELISA /IIFT

Ruggenenti P [6]

2015

No-As

55.7 ± 15.4

100/32

RB

9.1 (5.8–12.7)

1.21 (1.00–1.73)

144

25.8 (11.0–70.3)

49 (37.7)

NA

101

81 (80.2%)

20 (19.8%)

ELISA

Qin W [1]

2011

As

47.2 ± 15.4

16/44

RB

5.42 (4.39–7.61)

0.85 ± 0.5

> 12

3.0 (1.25–8.25)

NA

12 (6.5–22)

60

49 (81.7%)

11 (18.3%)

WB

Beck LH Jr [9]

2011

No-As

48.2 ± 11.1

5/30

RB

10.8 (5.7–26.5)

1.4 (1.00–1.80)

24

10 (6–17)

NA

NA

35

25 (71.4%)

10 (28.6%)

WB

Timmermans SA [16]

2015

No-As

52.4 ± 14.0

44/29

RB

6.7 (4.0–9.7)

0.97 (0.89–1.23)

34.8

NA

26 (35.6%)

NA

73

65 (89.0%)

8 (11.0%)

ELISA

Oh YJ [15]

2013

As

55.6 ± 13.9

56/77

RB

6.07 (3.17–9.86)

0.92 ± 0.35

30

NA

NA

2.0 (1.0–4.0)

77

56 (72.7%)

21 (27.3%)

WB

Kim YG [14]

2015

As

50.7 ± 15.0

15/19

RB

6.55 ± 3.61

0.76 ± 0.14

12

NA

NA

NA

93

41 (44.1%)

52 (55.9%)

ELISA

Bech AP [10]

2014

No-As

55(34–7)

10/37

RB

10.1 (3.2–25.2)

1.60 (0.98–3.37)

60

5 (1–26)

4 (8.3%)

NA

48

34 (70.8%)

14 (29.2%)

ELISA

Wei SY [8]

2016

As

48.2 ± 12.7

72/41

RB

10.78 ± 6.81

NA

≤20

NA

NA

NA

93

55 (59.1%)

38 (40.9%)

WB

Pourcine F [7]

2017

No-As

54(40.5–65.1)

32/53

RB

7.1 (3.5–10.8)

NA

168

NA

NA

NA

85

46 (54.1%)

22 (25.9%)

ELISA

Song EJ [17]

2018

As

55.35 ± 13.33

29/19

RB

6.20 ± 3.66

0.81 ± 0.33

65

NA

NA

NA

48

25 (52.1%)

23 (47.9%)

ELISA

  1. JASN J Am Soc Nephrol, CJSN Clin J Am Soc Nephrol, mo month, No-As none Asian, As Asian, M male, F female, PRO proteinuria, CREA serum creatinine, Fo follow up, TTR time to remission, RB renal-biopsy, DD disease duration, AM assay method, WB Western blotting, ELISA enzyme-linked immunosorbent assay, IIFT indirect immunofluorescence staining, IST immunosuppressive treatment